INTRODUCTION

Liver transplantation (LT) has become the treatment of choice for patients with end-stage liver disease because of improved results and broadening of indications. However, the shortage of organ donors and increased demand for LT have led to widening of concepts to increase the availability of grafts for LT. Acceptance of old and marginal liver donors, along with development of alternative techniques such as liver graft splitting, and the use of living donors and the domino procedure, have been proposed to reduce the mortality of patients on the waiting list. Although these...
procedures have increased the deceased donor organ pool, a profound shortage still remains.

Use of marginal donors, particularly older donors, is an important approach to expanding the donor pool [1,2]. Although favorable LT outcomes have been achieved with elderly donors [1-4], there is still a certain reluctance to use them due to concerns about early graft function and long-term graft survival. We present a retrospective analysis of our experience of adult deceased donor liver transplantation (DDLT) in a high-volume LT center using elderly donors aged ≥76 years.

**METHODS**

The study protocol was approved by the Institutional Review Board of Asan Medical Center, which waived the requirement for informed consent due to the retrospective nature of this study (IRB No. 2020-0857). This study was performed in accordance with the ethical guidelines of the World Medical Association Declaration of Helsinki 2013.

**Patient Selection and Study Design**

This study was a retrospective single-center analysis of DDLT data. Initially, the institutional LT database was searched to identify DDLT cases that used elderly donors ≥76 years of age during a 10-year period from January 2010 to December 2019. These LT cases were classified as the elderly donor study group. In addition, DDLT cases that received a graft from donors aged between 66 years and 75 years were used as an elderly donor control group. The study design was set to be a double-arm study comparing posttransplant outcomes between the study and control groups. The purpose was to ascertain whether using elderly donors had an adverse effect on the outcome of DDLT. Donor age was the only factor to classify the DDLT groups because detailed information on the donor condition and graft status was not available in the institutional medical record system. The patients in this study were followed up until April 2020.

**RESULTS**

**Patient Profiles**

The age of the 430 adult DDLT donors during the 10-year study period is depicted in Fig. 1. The number of donors aged ≥76 years and 66–75 years was 14 (3.3%; elderly donor study group) and 39 (9.1%; elderly donor control group), respectively. The donor and recipient characteristics within these two groups are presented in Table 1.

The mean donor age of the elderly donor study group was 78.2±3.1 years (range, 76–86 years), which was sig-

---

**HIGHLIGHTS**

- This was a retrospective double-arm analysis of adult deceased donor liver transplantation using elderly donors aged ≥76 years.
- The data suggest that organs from elderly donors do not worsen posttransplant outcomes.
- Advanced age should not be an exclusion criteria criterion; indeed, using such donors could be the key to increasing the supply of liver grafts.

---

**Statistical Analysis**

Numerical data are presented as the mean±standard deviation. Continuous variables were compared using Student t-test. Incidence variables were compared using the chi-square test and Fisher’s exact test. Survival rates were estimated using the Kaplan-Meier method and compared using the log-rank test. A P-value <0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS ver. 22 (IBM Corp., Armonk, NY, USA).

---

**Fig. 1.** Distribution of ages of deceased donors for a 10-year study period in Korea.
significantly higher than that of the control group (68.9±2.7 years). Other parameters were comparable between the two groups. The Model for End-Stage Liver Disease (MELD) scores for the elderly donor study and control groups were 31.0±9.3 and 32.2±9.9, respectively (P=0.72).

Posttransplant Survival Results
None of the cases that received grafts from the elderly donor study group survived longer than the control group (68.9±2.7 years). Other parameters were comparable between the two groups. The Model for End-Stage Liver Disease (MELD) scores for the elderly donor study and control groups were 31.0±9.3 and 32.2±9.9, respectively (P=0.72).

| Variable | Elderly donor study group (≥76 yr) | Elderly donor control group (66–75 yr) | P-value |
|----------|----------------------------------|--------------------------------------|---------|
| No. of patients | 14 | 39 | - |
| Recipient sex (male:female) | 11:3 | 25:14 | 0.44 |
| Recipient age (yr) | 50.8±11.5 | 51.1±13.3 | 0.93 |
| Primary disease | | | 0.91a |
| HBV-LC | 6 (42.9) | 16 (41.0) | |
| HCV-LC | 1 (7.1) | 0 | |
| ALD | 5 (35.7) | 11 (28.2) | |
| Others | 2 (14.3) | 12 (30.8) | |
| Recipient ABO blood group | | | 0.09b |
| A | 9 (64.3) | 12 (30.8) | |
| B | 4 (28.6) | 13 (33.3) | |
| O | 1 (7.1) | 8 (20.5) | |
| AB | 0 | 6 (15.4) | |
| Preoperative laboratory finding | | | |
| Total bilirubin (mg/dL) | 20.7±11.9 | 23.2±14.7 | 0.54 |
| Serum creatinine (mg/dL) | 1.52±0.96 | 2.21±2.11 | 0.11 |
| Prothrombin time (INR) | 2.29±0.91 | 2.41±0.89 | 0.71 |
| MELD score | 31.0±9.3 | 32.2±9.9 | 0.72 |
| Pretransplant ventilator support | 4 (28.6) | 11 (28.2) | 0.98 |
| Pretransplant renal replacement | 3 (21.4) | 16 (41.0) | 0.19 |
| HCC at explant liver | 5 (35.7) | 6 (15.4) | 0.11 |
| Donor sex (male:female) | 7:7 | 27:12 | 0.20 |
| Donor age (yr) | 78.2±3.1 | 68.9±2.7 | <0.001 |
| Graft type | NA | NA | |
| Whole liver | 14 (100) | 39 (100) | |
| Split right liver | 0 | 0 | |
| Graft weight (g) | 1181.9±239.5 | 1294.9±234.5 | 0.14 |
| Graft-recipient weight ratio | 1.59±0.53 | 1.98±0.84 | 0.42 |
| Donor anti-HBc IgG | 6 (42.9) | 19 (48.7) | 0.71 |
| Ischemic time (min) | | | |
| Cold | 285.6±136.9 | 299.1±89.7 | 0.81 |
| Warm | 56.3±56.4 | 59.4±58.4 | 0.78 |
| Retransplantation | NA | NA | |
| Early (<3 mo) | 0 | 1 (2.6) | |
| Late (>3 mo) | 0 | 3 (7.7) | |

Values are presented as mean±standard deviation or number (%).
HBV, hepatitis B virus; LC, liver cirrhosis; HCV, hepatitis C virus; ALD, alcoholic liver disease; INR, international normalization ratio; MELD, Model for End-Stage Liver Disease; HCC, hepatocellular carcinoma; NA, not available; anti-HBc IgG, hepatitis B virus core antibody immunoglobulin G.

a)Comparison between HBV-LC and other groups; b)Comparison between blood group A and B versus O and AB.
nor study group required retransplantation; however, four cases (10.3%) that received grafts from the elderly donor control group did: one patient required early retransplantation due to graft dysfunction and three patients required late retransplantation due to chronic rejection. The graft survival rates at 1, 3, and 5 years were 83.6%, 59.7%, and 12.3%.

Fig. 2. Comparison of graft (A) and overall patient (B) survival outcomes according to donor age.

A

B

Pretransplant ventilator (-)
Pretransplant ventilator (+)

Elderly control group
Elderly study group

P=0.97
P=0.74

0 1 2 3 4 5 6 7 8 9 10
Posttransplant year
Proportion of graft survival

0 1 2 3 4 5 6 7 8 9 10
Posttransplant year
Proportion of patient survival

Fig. 3. Comparison of the overall patient survival outcomes according to pretransplant ventilator support (A), pretransplant renal replacement therapy (B), Model for End-Stage Liver Disease (MELD) score with a cutoff of 31 (C), and retransplantation (D).

C

D

MELD score <31
MELD score ≥31
Retransplantation (-)
Retransplantation (+)

P=0.021
P=0.025
P=0.63
P=0.097

0 1 2 3 4 5 6 7 8 9 10
Posttransplant year
Proportion of patient survival

0 1 2 3 4 5 6 7 8 9 10
Posttransplant year
Proportion of patient survival
59.7%, respectively, for the elderly donor study group, and 79.4%, 68.1%, and 59.6%, respectively, for the elderly donor control group (P=0.97) (Fig. 2A).

The overall patient survival rates at 1, 3, and 5 years were 83.6%, 59.7%, and 59.7%, respectively, in the elderly donor study group and 79.3%, 72.1%, and 64.1%, respectively, in the elderly donor control group (P=0.74) (Fig. 2B). Four patients that received grafts from the elderly donor study group died due to posttransplant sepsis (n=1), late chronic rejection (n=1), and recurrence of hepatocellular carcinoma (n=2). Thus, peritransplant in-hospital mortality was one case (7.1%). By contrast, 13 patients (33.3%) that received grafts from the elderly donor control group died. Peritransplant in-hospital mortality occurred in six cases (15.4%), in which the underlying causes were graft dysfunction (n=2) and sepsis (n=4). Late mortality was caused by infection including pneumonia (n=3), chronic rejection (n=2), recurrence of hepatocellular carcinoma (n=1), and unknown causes (n=1).

**Risk Factor Analysis for Patient Survival**

Donor age was not a risk factor for patient survival; therefore, this parameter was excluded from the analysis. Univariate analysis revealed that pretransplant requirement for ventilator support (P=0.021) (Fig. 3A) and pretransplant requirement for renal replacement therapy were significant risk factors for overall survival (P=0.025) (Fig. 3B). A MELD score ≥31 was not a significant risk factor (P=0.63) (Fig. 3C). Retransplantation showed a noticeable prognostic contrast, but the significance was only marginal, primarily due to the small sample number (P=0.097) (Fig. 3D). Multivariate analysis did not identify pretransplant ventilator support, pretransplant renal replacement therapy, or retransplantation as independent risk factors (Table 2).

### DISCUSSION

During the 10 years from January 2010 to December 2019, there were 4,395 deceased donors registered in the Korean Network for Organ Sharing (KONOS) database, which included 21 elderly donors aged between 76–79 years and 21 donors aged ≥80 years. The 42 elderly donors aged ≥76 years represent 0.96% of all deceased donors. Considering that deceased donors allocated for pediatric DDLT were excluded from our series, the proportion of elderly donors aged ≥76 years was approximately 3% of all deceased donors allocated to our patients. This proportion of elderly donors appears to be much lower than that in Western countries in which organ donation is common [1-4].

Reports on utilization and optimization of elderly donor grafts for DDLT are conflicting. Some studies advocate the use of elderly donor organs for less sick recipients [5-8]. However, other reports show that the recipient’s MELD score has no effect on outcome after receiving a graft from an elderly donor [9,10]. These studies question the use of these “high-risk” donors in “low-risk” recipients. The results of our study show that a cutoff of MELD score of 31 is not a significant risk factor for patient survival. In real-world practice in Korea, such logical matching of high-risk donors to low-risk recipients is not possible due to a serious organ shortage [11]. By contrast, those in poor general condition and requiring pretransplant ventilator support...

### Table 2. Results of univariate and multivariate analyses for overall patient survival

| Variable                        | No. of cases | Univariate analysis 3-Year patient survival rate (%) | P-value | Multivariate analysis Hazard ratio (95% CI) | P-value |
|---------------------------------|--------------|------------------------------------------------------|---------|--------------------------------------------|---------|
| Pretransplant ventilatory support |              |                                                      |         |                                            |         |
| No                              | 38           | 80.5                                                 |         |                                            |         |
| Yes                             | 15           | 43.8                                                 | 0.021   | 2.41 (0.79–7.35)                           | 0.12    |
| Pretransplant renal replacement therapy |          |                                                      |         |                                            |         |
| No                              | 34           | 79.2                                                 |         |                                            |         |
| Yes                             | 19           | 56.0                                                 | 0.025   | 2.32 (0.76–6.94)                           | 0.13    |
| Retransplantation                |              |                                                      |         |                                            |         |
| No                              | 49           | 75.2                                                 |         |                                            |         |
| Yes                             | 4            | 25.0                                                 | 0.097   | 1.53 (0.35–3.42)                           | 0.32    |

CI, confidence interval.
support or renal replacement therapy are at significant risk of poor posttransplant outcomes, although multivariate analysis did not identify these as independent risk factors.

Some studies have examined the synergistic effects of donor age and cold ischemia time on graft survival after LT [12,13]. Prolonged cold ischemic time appears to be detrimental to the outcomes of elderly liver grafts; thus, we tried to shorten the cold and warm ischemic times as much as possible in such cases. However, we found no difference in the mean cold and warm ischemic times between the elderly study and control groups. Indeed, because the territory of South Korea is small, the cold ischemic time required for organ transportation is usually less than 4 hours. Thus, there is no need for time-saving donor-recipient matching in the current KONOS allocation system for DDLT.

Aging is characterized by a progressive decline in functions, which reduces the capacity of cells and organs to respond to intrinsic and extrinsic stimuli. Functional changes that develop with age should eventually lead to significant alterations in clinical practice. Synthetic, excretory, and metabolic changes in liver function may be affected by aging, and these effects may have clinical relevance [14]. The major age-related changes in the liver are reductions in tissue mass and blood flow. Here, we found that liver graft weight in the elderly study group was lower than that of the elderly control group. Indeed, there is an approximately 30% loss of liver volume and hepatic blood flow between the ages of 30 and 100 years [15].

Many studies show that using liver grafts from septuagenarian donors is not a contraindication to their utilization in DDLT per se [14]; however, some studies report significantly worse patient and graft survival when using liver grafts from donors older than 70 years [16-18]. Since the first reported case of successful graft from an 86-year-old donor [19], others have reported using liver grafts from octogenarian donors [2,14,20,21]; other studies have used grafts from nonagenarian donors [22-24].

Many studies of sexagenarian and septuagenarian donors demonstrate results that are similar to those obtained from younger donors. With respect to the use of octogenarian donors for DDLT, the general level of experience is less than that with grafts from younger donors. Therefore, to get good results using elderly liver grafts with no age limit, donors must be selected carefully according to strict criteria (normal liver function, good hemodynamic and pre-harvesting conditions, short intensive care unit stay, short cold and warm ischemic times, macrosteatosis <30%, absence of atherosclerosis in the hepatic artery, and absence of histological alterations in the biopsy) [14]. We think that the posttransplant results with elderly donors may improve if clinical factors are combined wisely with graft allocation. Because excellent outcomes can be achieved through strict donor selection, there may be no limit to the use of the octogenarian donors for stable patients [2].

This study has several limitations. It is a retrospective, single-center study with a relatively small number of patients. The choice as to whether to use an elderly liver graft was made on a case-by-case basis as there are no established guidelines. Further high-volume multicenter studies are necessary to validate the results of this study. In conclusion, the results of this study suggest that using an elderly donor graft might not worsen the posttransplant outcomes significantly; thus, advanced age per se may not be an absolute exclusion criterion for organ donation. Indeed, donor age factor has been considered for balancing the current supply and demand conundrum regarding liver grafts.

ACKNOWLEDGMENTS

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Funding/Support
This study was supported by research grant from the Korean Society for Transplantation (2021-00-01006-014).

ORCID
Minjae Kim https://orcid.org/0000-0001-6743-0636
Shin Hwang https://orcid.org/0000-0002-9045-2531
Chul-Soo Ahn https://orcid.org/0000-0002-3844-3646
Ki-Hun Kim https://orcid.org/0000-0002-4016-0995
Deok-Bog Moon https://orcid.org/0000-0002-8209-3540
Tae-Yong Ha https://orcid.org/0000-0001-9932-0212
Gi-Won Song https://orcid.org/0000-0002-4235-0434
Dong-Hwan Jung https://orcid.org/0000-0001-5984-023X
Gil-Chun Park https://orcid.org/0000-0003-1631-3258
Young-In Yoon https://orcid.org/0000-0002-9308-0366
Woo-Hyoung Kang https://orcid.org/0000-0002-3734-3352
Hwui-Dong Cho https://orcid.org/0000-0001-8501-3385
Byeong-Gon Na https://orcid.org/0000-0002-3150-4645
Author Contributions
Conceptualization: SH. Data curation: CSA, KHK, DBM, TYH, GWS, DHJ, GCP. Formal analysis: YIY, SGL. Methodology: WHK, HDC, BGN, SHK. Project administration: SH. Visualization: MK, SH. Writing—original draft: MK, SH. Writing—review & editing: SH.

REFERENCES

1. Paterno F, Wima K, Hoehn RS, Cuffy MC, Diwan TS, Woodle SE, et al. Use of elderly allografts in liver transplantation. Transplantation 2016;100:153-8.
2. Gastaca M, Guerra M, Alvarez Martinez L, Ruiz P, Ventoso A, Palomares I, et al. Octogenarian donors in liver transplantation. Transplant Proc 2016;48:2856-8.
3. Jiménez-Romero C, Caso Maestro O, Cambra Molero F, Justo Alonso I, Alegre Torrado C, Manrique Munici o A, et al. Using old liver grafts for liver transplantation: where are the limits? World J Gastroenterol 2014;20:10691-702.
4. Cascales-Campos PA, Ramírez P, González-Sánchez MR, Alc onchel F, Martínez-Insfran LA, Sánchez-Bueno F, et al. Orthotopic liver transplantation with elderly donors (over 80 years of age): a prospective evaluation. Transplant Proc 2018;50:3594-600.
5. Ozanhili DK, Li YF, Smith JK, Tseng JF, Saidi RF, Bozorgzadeh A, et al. Impact of center volume on outcomes of increased-risk liver transplants. Liver Transpl 2011;17:1191-9.
6. Kim DY, Moon J, Island ER, Tekin A, Ganz S, Levi D, et al. Liver transplantation using elderly donors: a risk factor analysis. Clin Transplant 2011;25:270-6.
7. Segev DL, Maley WR, Simpkins CE, Locke JE, Nguyen GC, Montgomery RA, et al. Minimizing risk associated with elderly liver donors by matching to preferred recipients. Hepatology 2007;46:1907-18.
8. Cameron AM, G侯rial RM, Yersiz H, Farmer DG, Lipshutz GS, Gordon SA, et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006;243:748-55.
9. Anderson CD, Vachharajani N, Doyle M, Lowell JA, Wellen JR, Shenoy S, et al. Advanced donor age alone does not affect patient or graft survival after liver transplantation. J Am Coll Surg 2008;207:847-52.
10. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008;8:419-25.
11. Min SI, Ahn C, Han DJ, Kim SI, Chung SY, Lee SK, et al. To achieve national self-sufficiency: recent progress in deceased donation in Korea. Transplantation 2015;99:765-70.
12. Cassuto JR, Patel SA, Tsoulfas G, Orloff MS, Abt PL. The cumulative effects of cold ischemic time and older donor age on liver graft survival. J Surg Res 2008;148:38-44.
13. Reese PP, Sonawane SB, Thomasson A, Yeh H, Markmann JF. Donor age and cold ischemia interact to produce inferior 90-day liver allograft survival. Transplantation 2008;85:1737-44.
14. Mooney H, Roberts R, Cooksley WG, Halliday JW, Powell LW. Alterations in the liver with ageing. Clin Gastroenterol 1985;14:757-71.
15. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301.
16. Busquets J, Xiol X, Figueras J, Jauretche E, Torsas J, Ramos E, et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation 2001;71:1765-71.
17. Lai Q, Melandro F, Levi Sandri GB, Mennini G, Corradini SG, Merli M, et al. Use of elderly donors for liver transplantation: has the limit been reached? J Gastrointestin Liver Dis 2011;20:383-7.
18. Fouzas I, Sgourakis G, Nowak KM, Lang H, Cincinnati VR, Molmenti EP, et al. Liver transplantation with grafts from septuagenarians. Transplant Proc 2008;40:3198-200.
19. Wall W, Grant D, Roy A, Asfar S, Block M. Elderly liver donor. Lancet 1993;341:121.
20. Jiménez Romero C, Moreno González E, Colina Ruiz F, Palma Carazo F, Loinaz Segurola C, Rodríguez González F, et al. Use of octogenarian livers safely expands the donor pool. Transplantation 1999;68:572-5.
21. Petridis I, Gruttadauria S, Nadalin S, Viganò J, di Francesco F, Pietrosi G, et al. Liver transplantation using donors older than 80 years: a single-center experience.
Transplant Proc 2008;40:1976-8.
22. Romagnoli J, Urbani L, Catalano G, Costa A, Marciano E, Filipponi F, et al. Liver transplantation using a 93-year-old donor. Transplant Proc 2001;33:3797.
23. Grazi GL, Cescon M, Rавaioli M, Corti B, Pinna AD. Successful liver transplantation from a 95-year-old donor to a patient with MELD score 36 and delayed graft arterialization. Am J Transplant 2008;8:725-6.
24. Karpen SJ. Growing old gracefully: caring for the 90-year-old liver in the 40-year-old transplant recipient. Hepatology 2010;51:364-5.